福辛普利联合依帕司他片治疗糖尿病肾病的疗效观察

目的 研究福辛普利联合依帕司他片治疗糖尿病肾病的疗效。方法 选择2016年1月-2017年12月新疆喀什第三师医院收治的60例糖尿病肾病患者，随机分为两组。对照组口服依帕司他片治疗，每次50 mg，每天3次。观察组联合口服福辛普利钠片，每次20 mg，每天1次。两组均治疗4周。比较两组的疗效以及治疗前后的肾功能、氧化应激指标改变情况。结果 观察组的有效率为86.67%，显著高于对照组的70.00%（P<0.05）。治疗后，两组患者的尿素氮（BUN）、24 h尿蛋白和血肌酐（Scr）均较治疗前显著降低（P<0.05），且观察组显著低于对照组（P<0.05）。治疗后两组的丙二醛（MDA）值较治疗前显著降低（P<0.05），总抗氧化能力（T-AOC）和超氧化物歧化酶（SOD）水平均较治疗前显著升高（P<0.05），且观察组显著优于对照组（P<0.05）。结论 福辛普利联合依帕司他片在减少糖尿病肾病患者全身氧化应激、改善肾功能方面均具有积极作用，可显著提高疗效，值得应用推广。

Efficacy of Epalrestat Tablets combined with fosinopril in treatment of diabetic nephropathy

Objective To investigate the effect of Epalrestat Tablets combined with fosinopril in treatment of diabetic nephropathy. Methods Selected 60 cases of patients with diabetic nephropathy who were treated in our hospital from January 2016 to December 2017, divided into two groups randomly. The control group was treated with Epalrestat Tablets alone, and the observation group combined with oral Phu Simpson Leigh treatment. The curative effects of two groups were compared, and the changes of renal function and oxidative stress index before and after treatment were compared. Results The effective rate of the observation group was significantly higher than control group (P<0.05). After treatment, BUN, 24-hour urinary protein and SCR in both groups were significantly decreased (P<0.05), and those in the observation group were significantly lower (P<0.05). After treatment, MDA values in both groups were significantly decreased (P<0.05), T-AOC and SOD values were significantly increased (P<0.05), especially in the observation group (P<0.05). Conclusion Epalrestat tablets combined with fosinopril have positive effects on reducing systemic oxidative stress and improving renal function in patients with diabetic nephropathy, which can significantly improve the curative effect.